12421/16820US=84-A / Biol/Mol
Pardali E, Liu Z, Scharpfenecker M, Dijke P. Transformig growth factor-B in developing and advanced cancers: TGF-B signaling and vascular morphogenesis. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 507-21. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; HHT; ANGIOGENESE; ENDOGLINA; HHT; TRANSDUCAO DE SINAL

12422/16820US=84-A / Biol/Mol
Suzuki E, Albelda SM. Development of inhibitors of transforming growth factor-B signaling for therapy: soluble type II transforming growth factor-B receptor inhibits tumorigenesis by augmenting host ntitumor immunity. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 697-706. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; IMUNIDADE ANTITUMORAL; MESOTELIOMA MALIGNO; SOLUVEL DO TIPO II DO RECEPTOR DE TGF-B

12423/16820US=84-A / Biol/Mol
Lacher MD, Korn WM, Akhurst RJ. Development of inhibitors of transforming growth factor-B signaling for therapy: reversal of EMT by small-molecule inibitors of TGF-B type I and II receptors: implications for carcinoma treatment. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 707-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B RECEPTORES; PEQUENAS MOLECULAS INIBIDORES; EPITELIAL PARA MESEACHYMAL TRANSICAO; EMT; METASTASE; VIRUS COXSACKIE E RECEPTOR ADENOVIRUS; TERAPIA DO CANCRO ADENOVIRAL

12424/16820US=86 / Biol/Mol
Zakeri Z, Lockshin RA. Cell dealth: history and future. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 1-11. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

MORTE CELULAR; APOPTOSE; AUTOFAGIA; MORTE CELULAR AUTOFAGICA; HISTORICO; LISOSSOMA

12425/16820US=86 / Biol/Mol
Salvesen GS, Riedl SJ. Caspase mechanisms. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 13-23. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

CASPASE; MECANISMOS DE CASPASE; APOPTOSSOMO; DISC; IAP; INIBICAO; PROTEASE; ZIMOGENIO; APOPTOSE

12426/16820US=86 / Biol/Mol
Chalah A, Khosravi-Far R. The mitochondrial death pathway. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 25-45. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

VIA DE MORTE MITOCONDRIAL; APOPTOSE; RECEPTORES DE MORTE; MITOCONDRIAS; MEMBRANAS; FOSFOLIPASES; CARDIOLIPINA; LIBERACAO DE FATORES PRO-APOPTOTICOS; CITOCROMO C; FATOR DE INDUCAO DE APOPTOSE; SMAC / DIABLO; HTRA2/OMI; ENDONUCLEASE G; PROTEINAS MITOCONDRIAIS; ATIVACAO DA CASPASE; FAMILIA BCL-2; STRESS OXIDATIVO; CANCER

12427/16820US=86 / Biol/Mol
Melet A, Song K, Bucur O, Jagani Z, Grassian AR, Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 47-79. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

VIAS APOPTOTICAS; PROGRESSAO TUMORAL; TERAPIA DE CANCER; APOPTOSE; INIBIDORES; TRANSDUCAO DE SINAL; ONCOGENE; MAQUINARIA APOPTOTICA; DROGAS QUIMIOTERAPICAS; RESISTENCIA A DROGA

12428/16820US=86 / Biol/Mol
Tan TT, White E. Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 81-104. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

SEGMENTACAO TERAPEUTICO; VIAS DE MORTE EM CANCER; MECANISMOS; MORTE CELULAR; CELULAS CANCERIGENAS; APOPTOSE; QUIMIOTERAPIA; TERAPIA ALVO; FAMILIA BCL-2; RECEPTORES DE MORTE; INIBIDORES DO SINAL DE TRANSDUCAO

12429/16820US=86 / Biol/Mol
Hersey P, Zhang XD, Mhaidat N. Overcoming resistance to apoptosis in cancer therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 105-26. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

TERAPIA DO CANCER; RESISTENCIA A APOPTOSE; ONCOGENE; MELANOMA; FAMILIA BCL-2

12430/16820US=86 / Biol/Mol
Humphreys RC, Halpern W. Trail receptors: targets for cancer therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 127-58. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

TERAPIA DO CANCER; RECEPTORES TRAIL; APOPTOSE; ANTICORPOS MONOCLONAIS

12431/16820US=86 / Biol/Mol
Moore VDG, Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 159-75. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

MORTE CELULAR; APOPTOSE; FAMILIA BCL-2; BH3; TERAPEUTICA; PEPTIDEOS

12432/16820US=86 / Biol/Mol
Bialik S, Kimchi A. Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 177-200. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

AUTOFAGIA; SUPRESSAO DO TUMOR; AUTOFAGICOS; VIAS DE MORTE CELULAR; DESENVOLVIMENTO DE TUMORES; MORTE CELULAR PROGRAMADA; DAPK; BECLIN 1; MTOR

12433/16820US=86 / Biol/Mol
Kuribayashi K, El-Deiry W. Regulation of programmed cell death by the P53 pathway. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 201-21. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

REGULACAO DA MORTE CELULAR PROGRAMADA; VIA P53; APOPTOSE; TRANSCRICAO; RECEPTORES TRAIL; MORTE CELULAR DEPENDENTES DE P53

12434/16820US=86 / Biol/Mol
Fan Y, Dutta J, Gupta N, Fan G, Gélinas C. Regulation of programmed cell death by NF-kB and its role in tumorigenesis and therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 223-50. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

REGULACAO DA MORTE CELULAR; NF-KB; TUMORIGENESE; TERAPIA; APOPTOSE; NECROSE; FATOR DE TRANSCRICAO; CANCER

12435/16820US=86 / Biol/Mol
Chauhan D, Hideshima T, Anderson KC. Targeting proteasomes as therapy in multiple myeloma. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 251-60. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

PROTEOSOMAS; SEGMENTACAO; TERAPIA; MIELOMA MULTIPLO; APOPTOSE; RESISTENCIA A DROGA; BORTEZOMIBE

12436/16820US=86 / Biol/Mol
Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HAC inhibitor-induced apoptosis. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 261-98. (Advances in Experimental Medicina and Biology volume 615) ISBN 978-1-4020-6553-8.

INIBIDORES DE HISTONA DESACETILASE; CANCER; APOPTOSE INDUZIDA POR INIBIDORES; INIBIDORES HDAC; HAT; SAHA; MS-275; TSA; TRAIL; CASPASE

12437/16820US=86 / Biol/Mol
Dykxhoorn DM, Chowdhury D, Lieberman J. RNA interference and cancer: endogenous pathways and therapeutic approaches. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 299-329. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

RNA DE INTERFERENCIA; CANCER; VIAS ENDOGENAS; MICRORNA; MICROARRAY; PERFIL DO TUMOR; SIRNA; PROGNOSTICO; TERAPIA

12438/16820US=86 / Biol/Mol
Jagani Z, Khosravi-Far R. Cancer stem cells and impaired apoptosis. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 331-44. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

CELULAS-TRONCO; CANCER; APOPTOSE; TERAPIA; LEUCEMIA; WNT; BMI1

12439/16820US=61 / Mono/Fono
Tega LPV. Médicos residentes: conhecimento em deglutição e disfagia. São Paulo: FAP, 2011. 18 p. -[Monografia de Conclusão do Curso de Pós-Graduação Lato Sensu Disfagia Hospitalar Fundação Antonio Prudente.

CORPO CLINICO HOSPITALAR; DEGLUTICAO; TRANSTORNOS DE DEGLUTICAO; COMPETENCIA CLINICA; ESTUDO DE COORTES; QUESTIONARIOS

12440/16820US=217 / Mono/Enfermagem
Galrão VCS. Transplante de células tronco hematopoiético no pacientes pediátricos e GVHD: uma revisão de literatura. São Paulo, 2012. 42 p. -[Monografia de Conclusão do Curso de Pós Graduação Lato Sensu Enfermagem Oncológica Fundação Antonio Prudente].

DOENCA ENXERTO-HOSPEDEIRO; CRIANCA; TRANSPLANTE DE MEDULA OSSEA; CELULAS TRONCO HEMATOPOIETICAS

Primeira | Anterior | Próxima | Última